Home > Inhibitors & Agonists > Tyrosine Kinase > BTK
Cat. No. Product name CAS No.
DC11707 MDVN-1003

A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.

2058116-54-2
DC11804 IQS-019

A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively.

1630804-24-8
DC11805 IQS-019 mesylate

A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively.

1630804-27-1
DC9660 Acalabrutinib(ACP196)

Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK.

1420477-60-6
DC10975 ARQ-531

ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM,

2095393-15-8
DC5014 AVL-292

AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed.

1202757-89-8
DC10335 BGB-3111

BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.

1633350-06-7
DC11819 BMS-986142

BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM).

1643368-58-4
DC12030 BMS-986195

BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK).

1912445-55-6
DC7380 CGI-1746

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.

910232-84-7
DC10380 Evobrutinib

Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.

1415823-73-2
DC7937 LFM-A13

FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK).

244240-24-2
DC11776 G-744

G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.

1346669-54-2
DC9942 GDC-0853(RG7845)

GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

1434048-34-6
DC10043 ONO4059 hydrochloride

ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.

1439901-97-9
DC8358 ONO-4059

ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase.

1351636-18-4
DC10757 PCI-29732

PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.

330786-25-9
DC1106 PCI-32765 (Ibrutinib)

PCI-32765 (Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM.

936563-96-1
DC11914 Poseltinib

Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM.

1353552-97-2
DC5146 RN486

RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor.

1242156-23-5
DC10044 ONO4059 analog

The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.

1351635-67-0
DC11471 BGB-3111(Zanubrutinib)

Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

1691249-45-2
Page 1 / Total 1 FirstPrevNextLastGoto